|  HOME   |  Login   |  회원가입   |  사이트맵   |  Contact Us
인사말   /  조직도   /  임원진   /  위원회   /  학회 회칙
투고규정
학회지 검색
학회 소식지
학회지 검색 -
Journal of Multiple Sclerosis 7(2):49-54, 2016
Alemtuzumab in the Treatment of Multiple Sclerosis
Jeeyoung Oh
Department of Neurology, Konkuk University Medical Center, Seoul, Korea
Alemtuzumab is a humanized monoclonal antibody against CD52 and is recently approved for the second-line therapy of active relapse-remitting multiple sclerosis in Korea. Alemtuzumab leads to a rapid and long-lasting depletion of peripheral T and B cells with repopulation of immune cell composition resulting in the rebalancing of immune-tolerance network. However, it has a considerable adverse effects including infusion associated reaction, infection, and secondary autoimmune disease requiring close and regular monitoring during and for 4 years after the final infusion cycle. This review will provide a summary of mechanism of action, data from the pivotal clinical studies, and safety profiles of alemtuzumab.

Journal of Multiple Sclerosis 7(2):49-54, 2016
KEY WORDS : Alemtuzumab, CD52, Monoclonal antibody, Multiple sclerosis